Targeting ovarian cancer and chemoresistance through selective inhibition of sphingosine kinase-2 with ABC294640

Anticancer Research

Volumn 33, Issue 9, 2013, Pages 3573-3580

  White, Martin D ^a   Chan, Lucas ^a   Antoon, James W ^a   Beckman, Barbara S ^a  

^a TULANE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

ABC294640; BG 1; Caov 3 cells; Chemoresistance; Experimental therapeutics; Ovarian cancer; Sphingolipids; Sphingosine kinase 2; Sphingosine 1 phosphate

Indexed keywords

[3 (4 CHLOROPHENYL) ADAMANTANE 1 CARBOXYLIC ACID (PYRIDIN 4 YLMETHYL) AMIDE]; ABC 294640; ANTINEOPLASTIC AGENT; CASPASE 9; PACLITAXEL; PHOSPHOTRANSFERASE INHIBITOR; PROTEIN BAX; SPHINGOSINE KINASE 2; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; AUTOPHAGY; CANCER RESISTANCE; CELL CYCLE REGULATION; CELL SURVIVAL; CELL VIABILITY; COLONY FORMATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME INHIBITION; OVARY CANCER; PRIORITY JOURNAL; PROTEOMICS;

ABC294640; BG-1; CAOV-3 CELLS; CHEMORESISTANCE; EXPERIMENTAL THERAPEUTICS; OVARIAN CANCER; SPHINGOLIPIDS; SPHINGOSINE KINASE-2; SPHINGOSINE-1-PHOSPHATE;

ADAMANTANE; ANTINEOPLASTIC AGENTS; APOPTOSIS; BCL-2-ASSOCIATED X PROTEIN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FEMALE; HUMANS; OVARIAN NEOPLASMS; PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PYRIDINES;

EID: 84884992556     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Society AC: Cancer Facts and Figures 2013. 2013; http:// www.cancer.org/acs/groups/content/@epidemiologysurveilance/d ocuments/document/acspc-036845.pdf. Accessed March 3rd, 2013.
2. Hait NC, Oskeritzian CA, Paugh SW, Milstien S and Spiegel S: Sphingosine kinases, sphingosine 1-phosphate, apoptosis and diseases. Biochim Biophys Acta 1758(12): 2016-2026, 2006.
3. Huwiler A and Pfeilschifter J: Altering the sphingosine-1-phosphate/ ceramide balance: a promising approach for tumor therapy. Curr Pharm Des 12(35): 4625-4635, 2006.
4. Huwiler A and Zangemeister-Wittke U: Targeting the conversion of ceramide to sphingosine 1-phosphate as a novel strategy for cancer therapy. Crit Rev Oncol Hematol 63(2): 150-159, 2007.
5. Hla T: Signaling and biological actions of sphingosine 1-phosphate. Pharmacol Res 47(5): 401-407, 2003.
6. Huwiler A, Kolter T, Pfeilschifter J and Sandhoff K: Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485(2-3): 63-99, 2000.
7. Van Brocklyn JR, Young N and Roof R: Sphingosine-1-phosphate stimulates motility and invasiveness of human glioblastoma multiforme cells. Cancer Lett 199(1): 53-60, 2003.
8. Takabe K, Paugh SW, Milstien S and Spiegel S: "Inside-out" signaling of sphingosine-1-phosphate: therapeutic targets. Pharmacol Rev 60(2): 181-195, 2008.
9. Maceyka M, Harikumar KB, Milstien S and Spiegel S: Sphingosine-1- phosphate signaling and its role in disease. Trends Cell Biol 22(1): 50-60, 2012.
10. Liu H, Toman RE, Goparaju SK et al: Sphingosine kinase type 2 is a putative BH3-only protein that induces apoptosis. J Biol Chem 278(41): 40330-40336, 2003.
11. Maceyka M, Sankala H, Hait NC et al: SphK1 and SphK2, sphingosine kinase isoenzymes with opposing functions in sphingolipid metabolism. J Biol Chem 280(44): 37118-37129, 2005.
12. Gao P and Smith CD: Ablation of sphingosine kinase-2 inhibits tumor cell proliferation and migration. Mol Cancer Res 9(11): 1509-1519, 2011.
13. Schnitzer SE, Weigert A, Zhou J and Brune B: Hypoxia enhances sphingosine kinase 2 activity and provokes sphingosine-1-phosphate-mediated chemoresistance in A549 lung cancer cells. Mol Cancer Res 7(3): 393-401, 2009.
14. Xiao M, Liu Y and Zou F: Sensitization of human colon cancer cells to sodium butyrate-induced apoptosis by modulation of sphingosine kinase 2 and protein kinase D. Exp Cell Res 318(1): 43-52, 2012.
15. French KJ, Zhuang Y, Maines LW et al: Pharmacology and antitumor activity of ABC294640, a selective inhibitor of sphingosine kinase-2. J Pharmacol Exp Ther 333(1): 129-139, 2010.
16. Beljanski V, Lewis CS and Smith CD: Antitumor activity of sphingosine kinase 2 inhibitor ABC294640 and sorafenib in hepatocellular carcinoma xenografts. Cancer Biol Ther 11(5): 524-534.
17. Antoon JW, White MD, Meacham WD et al: Antiestrogenic effects of the novel sphingosine kinase-2 inhibitor ABC294640. Endocrinology 151(11): 5124-5135, 2010.
18. Antoon JW, White MD, Slaughter EM et al: Targeting NFkB mediated breast cancer chemoresistance through selective inhibition of sphingosine kinase-2. Cancer Biol Ther 11(7): 678-689, 2011.
19. Antoon JW, Meacham WD, Bratton MR et al: Pharmacological inhibition of sphingosine kinase isoforms alters estrogen receptor signaling in human breast cancer. J Mol Endocrinol 46(3): 205-216, 2011.
20. Beljanski V, Knaak C and Smith CD: A novel sphingosine kinase inhibitor induces autophagy in tumor cells. J Pharmacol Exp Ther 333(2): 454-464, 2010.
21. Strobel T, Swanson L, Korsmeyer S and Cannistra SA: BAX enhances paclitaxel-induced apoptosis through a p53-independent pathway. Proc Natl Acad Sci USA 93(24): 14094-14099, 1996.
22. Concin N, Stimpfl M, Zeillinger C et al: Role of p53 in G2/M cell cycle arrest and apoptosis in response to gamma-irradiation in ovarian carcinoma cell lines. Int J Oncol 22(1): 51-57, 2003.
23. Tai YT, Lee S, Niloff E, Weisman C, Strobel T and Cannistra SA: BAX protein expression and clinical outcome in epithelial ovarian cancer. J Clin Oncol 16(8): 2583-2590, 1998.
24. Maiuri MC, Zalckvar E, Kimchi A and Kroemer G: Self-eating and self-killing: Crosstalk between autophagy and apoptosis. Nat Rev Mol Cell Biol 8(9): 741-752, 2007.